The HCL Cancer Institute details its 2030 roadmap

Created in 2014, the Cancer Institute of the Hospices Civils de Lyon (HCL) presented at a conference organized at the end of December an assessment of its action and detailed its roadmap for the next five years.

With 15,132 patients treated in 2023 including 8,790 new cases, the Cancer Institute is the leading player in the treatment of cancer in the Auvergne-Rhône-Alpes region. The establishment welcomes patients from the Rhône (55%), the region (36%) as well as from throughout France and even from abroad for rare tumors or revisions following incorrect prognoses.
In 2023, more than 3,000 patients have been included in clinical trials and nearly 1,600 in interventional trials. In addition, 189 early phase trials are underway.

Establish “cancer entry points”

Concretely, the next five years of the HCL Cancer Institute will be structured around the following six axes: preventing and intercepting the disease as early as possible; facilitate access to care, everywhere and for everyone, by building pathways with patients and caregivers coordinated with the city and regional sectors; allow all patients “to access multidisciplinary and integrative precision medicine” throughout their care journey; move towards excellent patient-centered cancer research; preserve quality of life during treatments and support post-cancer; and finally cure cancer thanks to innovations in surgery, radiotherapy and interventional oncology.

AI has all stages of the disease

AI, bioinformatics and predictive models will be used at all stages of the disease. As a reminder, 40% of cancers are preventable through screening and prevention.

The Hospices Civils de Lyon should also launch a mobile lung cancer screening truck called Mob’ILYAD in April 2025. In mirror image, the ARS also aims to better coordinate the hospital and the city, to improve the complex pathways of vulnerable populations and facilitate access for all patients to therapeutic innovations.

President of the National Cancer Institute, Professor Norbert Ifrah praised the success of this Institute and outlined avenues for the future of the sector. According to the expert, “optimizing entry into care is one of the essential challenges of the second half of the ten-year strategy to combat cancer, in particular through the identification of “cancer entry points” visible from the city ». Professor Ifrah insisted on the need for public hospitals to “take charge of prevention and screening”. Finally, he underlined the importance of structuring post-cancer treatment and mobilizing available data to better characterize care pathways.